Xencor, Inc. (XNCR)

US — Healthcare Sector
Peers: PROK  NKTR  BCAX  TNGX  MNMD  PGEN  ANAB  PHAT  KURA  RLAY 

Automate Your Wheel Strategy on XNCR

With Tiblio's Option Bot, you can configure your own wheel strategy including XNCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol XNCR
  • Rev/Share 2.21
  • Book/Share 8.3516
  • PB 1.7685
  • Debt/Equity 0.3433
  • CurrentRatio 5.3407
  • ROIC -0.1537

 

  • MktCap 1053441389.0
  • FreeCF/Share -1.8957
  • PFCF -7.4811
  • PE -6.1682
  • Debt/Assets 0.2422
  • DivYield 0
  • ROE -0.2673

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed XNCR Barclays -- Underweight -- $6 Sept. 17, 2025
Downgrade XNCR BofA Securities Buy Neutral -- $12 Sept. 3, 2025
Initiation XNCR William Blair -- Outperform -- -- April 21, 2025
Initiation XNCR Wells Fargo -- Overweight -- $37 Dec. 12, 2024

News

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
XNCR
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma.

Read More
image for news Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
XNCR
Published: October 14, 2025 by: Business Wire
Sentiment: Neutral

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation of initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC) in a poster at the AACR-NCI-EORTC Conference on Molecular Targets an.

Read More
image for news Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
XNCR
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Read More
image for news Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
XNCR
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.

Read More
image for news Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) Upgraded to Buy: Here's Why
XNCR
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Xencor (XNCR) Upgraded to Buy: Here's Why

About Xencor, Inc. (XNCR)

  • IPO Date 2013-12-03
  • Website https://www.xencor.com
  • Industry Biotechnology
  • CEO Bassil I. Dahiyat
  • Employees 250

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.